Abstract
White adipose tissue regulates metabolism; the importance of this control is highlighted by the ongoing pandemic of obesity and associated complications such as diabetes, atherosclerosis, and cancer. White adipose tissue maintenance is a dynamic process, yet very little is known about how pharmacologic stimuli affect such plasticity. Combining in vivo lineage marking and BrdU labeling strategies, we found that rosiglitazone, a member of the thiazolidinedione class of glucose-lowering medicines, markedly increases the evolution of adipose progenitors into adipocytes. Notably, chronic rosiglitazone administration disrupts the adipogenic and self-renewal capacities of the stem cell compartment and alters its molecular characteristics. These data unravel unknown aspects of adipose dynamics and provide a basis to manipulate the adipose lineage for therapeutic ends.
Original language | English (US) |
---|---|
Pages (from-to) | 116-122 |
Number of pages | 7 |
Journal | Cell Metabolism |
Volume | 14 |
Issue number | 1 |
DOIs | |
State | Published - Jul 6 2011 |
ASJC Scopus subject areas
- Physiology
- Molecular Biology
- Cell Biology